Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y)
Articolo
Data di Pubblicazione:
2017
Citazione:
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) / Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 163:3(2017), pp. 637-637. [10.1007/s10549-017-4219-3]
Abstract:
In the original publication of the article, the eighth and ninth co-author’s affiliations were published incorrectly. The correct affiliations of the co-authors are given in this erratum.
Tipologia CRIS:
Articolo su rivista
Elenco autori:
Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: